An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee

Trial Profile

An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Musculoskeletal pain
  • Focus Adverse reactions
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Flexion Therapeutics media release, final data readout is expected in the second half of 2018.
    • 08 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to a Flexion Therapeutics media release.
    • 04 May 2017 According to a Flexion Therapeutics media release, the trial is expected to be fully enrolled in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top